.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD10_Darifenacin.Darifenacin

Information

Darifenacin is a selective muscarinic M3 receptor antagonist used to treat symptoms of overactive bladder, such as urinary incontinence, urgency, and frequency. It is approved for clinical use and is commonly administered orally.

Pharmacokinetics

Pharmacokinetics in healthy adult volunteers after repeated oral administration.

References

1. Kerbusch, T, et al., & Karlsson, MO (2003). Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. British journal of clinical pharmacology 56(6) 639–652. DOI:10.1046/j.1365-2125.2003.01967.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14616424

2. McFerren, SC, & Gomelsky, A (2015). Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. Drugs & aging 32(10) 809–819. DOI:10.1007/s40266-015-0301-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/26391900

3. Kerbusch, T, et al., & Karlsson, MO (2004). Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. British journal of clinical pharmacology 57(2) 170–180. DOI:10.1046/j.1365-2125.2003.01988.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/14748816

Revisions

• 06/2025 initial generated model